Posted on April 24, 2019 by Sitemaster
A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …
Filed under: Uncategorized | Tagged: 18F-DCFPyL, biochemical, change, CT, imaging, Management, PET, recurrence, scan | Leave a comment »
Posted on January 7, 2019 by Sitemaster
A research team at the University of California, Los Angeles (UCLA) is seeking participants for a randomized, Phase III, clinical trial of the utility of 68Ga-PSMA-11 PET/CT molecular imaging for planning of salvage radiotherapy after first-line treatment for localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CT, free, gallium-68, PET, PSMA-11, radiation, salvage, scan, SRT, therapy | 4 Comments »
Posted on September 12, 2018 by Sitemaster
A newly-reported set of data from an Australian clinical research team has now shown that 68Ga PSMA PET/CT scans changed the staging and the management of men after initial diagnosis and prior to first-line treatment compared to traditional CT and bone scanning. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: CT, gallium-68, PET, PSMA, risk, scan | 1 Comment »
Posted on June 16, 2017 by Sitemaster
Here in the USA, about half the patients diagnosed with low-risk prostate cancer are still (apparently) being sent for “guideline-discordant” (i.e., unnecessary) bone scans and CT scans, … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: appropriate, bone, CT, inappropriate, scan, why | 2 Comments »
Posted on February 26, 2016 by Sitemaster
A new review article suggests the possibility that radiolabeled prostate specific membrane antigens (PSMAs) and PET scans may, at some point in the not too distant future, replace bone and CT scans in diagnosis and monitoring of men with advanced forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management | Tagged: bone, CT, gallium-68, PET, PSMA, scan | 4 Comments »
Posted on October 23, 2015 by Sitemaster
A newly published paper in the journal Cancer seems to be implying that every man with castration-resistant prostate cancer who progresses from non-metastatic to metastatic status (based on a bone scan or other indicators) should also be given a CT scan because of risk for soft tissue metastasis. … READ MORE … >
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bone, castration-resistant, CRPC, CT, metastasis, scan | 8 Comments »
Posted on March 13, 2015 by Sitemaster
A new paper in JAMA Oncology has shown that between 2004 and 2007 nearly 45 percent of men initially diagnosed with low-risk prostate cancer were receiving unnecessary bone scans and CT scans in some regions of the USA. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: bone, CT, imaging, risk, scan, test | 3 Comments »
Posted on July 25, 2013 by Sitemaster
An article published a couple of weeks ago in the Journal of the National Cancer Institute looks at the effects of a physician education campaign in Sweden to reduce the inappropriate use of bone scans and other imaging tests among men with an initial diagnosis of low-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: bone, CT, imaging, low risk, scan | 2 Comments »
Posted on June 20, 2009 by Sitemaster
Today’s news reports cover just two recent review articles, on:
- Current indications for repeat biopsy
- MRI, CT, and PET scanning in prostate cancer patients with biochemical progression after first line therapy … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: biochemical progression, biopsy, CT, MRI, PET, repeat, scan | Leave a comment »